Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amibegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 12/20 | 0.91 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amibegron SCHEMBL8765764 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL2052478 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL29373533 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3824162 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL6931932 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL5200899 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9006793 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3908665 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9317343 | 0.99 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3897916 | 0.99 | ADRB3 (0.89) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1382333-B1 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | ASTELLAS PHARMA INC (JP) | 2009-02-25 | — | — | EP | claimed |
| EP-3463312-A1 | DOSING REGIMENS FOR BETA-3 ADRENOCEPTOR AGONISTS AND ANTI-MUSCARINIC AGENTS FOR THE TREATMENT AND PREVENTION OF LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER | Velicept Therapeutics, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017210696-A1 | DOSING REGIMENS FOR BETA-3 ADRENOCEPTOR AGONISTS AND ANTI-MUSCARINIC AGENTS FOR THE TREATMENT AND PREVENTION OF LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER | VELICEPT THERAPEUTICS, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20140227289-A1 | COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-08-14 | — | — | US | disclosed |
| WO-2012158123-A1 | COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-11-22 | — | — | WO | disclosed |